Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The partnership will capitalize on the combined capabilities of the two organizations
Subscribe To Our Newsletter & Stay Updated
